Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Iofina Plc LSE:IOF London Ordinary Share GB00B2QL5C79 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.30 -2.34% 12.50 387,038 08:22:58
Bid Price Offer Price High Price Low Price Open Price
12.00 13.00 12.875 12.25 12.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 29.25 0.55 0.30 41.7 24
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:45 O 50,000 12.50 GBX

Iofina (IOF) Latest News

More Iofina News
Iofina Investors    Iofina Takeover Rumours

Iofina (IOF) Discussions and Chat

Iofina (IOF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-22 17:07:4512.5050,0006,250.00O
2021-01-22 16:09:2612.7518,3052,333.89O
2021-01-22 16:09:2512.7528,1963,594.99O
2021-01-22 16:04:4512.7750,0006,385.00O
2021-01-22 14:52:2812.756,000764.70O
View all Iofina trades in real-time

Iofina (IOF) Top Chat Posts

DateSubject
23/1/2021
08:20
Iofina Daily Update: Iofina Plc is listed in the General Financial sector of the London Stock Exchange with ticker IOF. The last closing price for Iofina was 12.80p.
Iofina Plc has a 4 week average price of 12.25p and a 12 week average price of 10.63p.
The 1 year high share price is 26p while the 1 year low share price is currently 10.50p.
There are currently 191,858,408 shares in issue and the average daily traded volume is 647,472 shares. The market capitalisation of Iofina Plc is £23,982,301.
19/1/2021
08:27
abid6814: Underwhelming update with the odd bright spot.Ultimately if this was a great update we would all be rushing to buy more stock and the market is the ultimate judge in terms of share price movement.As with most updates, basic financial information is missing. Production targets are conservative, that's fine but care to explain why? No we are Iofina.Continued mystery around increased investment in the chemical division which I support but no translation or read across to to impacts on future revenue and profits, care to explain why? No we are Iofina.As for the Seeds, whilst most hemp stocks are rising again due to regulatory changes and the Democrats coming in we continue to aim to flog our vintage seeds to anyone that will have them. Have you sold any, we can't tell you we are Iofina!More transparency please... I really do hope we get an AGM this year to ask real questions and get real answers. I applaud how we have navigated the challenges of 2020 but want to see more fire in the leadership team, more detail in their updates and serious commitment to developing and executing a strategy that delivers shareholder value.....
19/1/2021
07:03
chumbo1: Iofina PLC Market UpdateSource: UK Regulatory (RNS & others)TIDMIOFRNS Number : 0875MIofina PLC19 January 202119 January 2021Iofina plc("Iofina", the "Group", or the "Company")(LSE AIM: IOF)Market UpdateRecord 2020 Iodine ProductionIofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update to the market regarding 2020 Group performance, a year in which it produced a record volume of crystalline iodine and continued to execute on its strategy.2020 Highlights: -- Record full-year of iodine production o Full-year 2020 production of 609.9 metric tonnes ('MT') of crystalline iodine (FY2019: 602.7MT)o H2 crystalline iodine production of 325.5MT (H2 2019: 316MT), an increase of 14 per cent over H1, the highest production of any half-year in Company history -- IO#8 completed on time and on budget at a total cost of $3.1m o The Company now operates five iodine production plants in western Oklahoma -- Corporate debt restructured and balance sheet greatly strengthened o Debt significantly reduced whereby current total debt is less than half of the debt 24 months prioro Interest rates on debt considerably reduced -- Exploration efforts for future iodine production opportunities continued and are ongoing -- Expansion of the Group's board with appointment of Mary Fallin, the recent Governor of the State of Oklahoma in the United States -- Iofina Chemical's non-iodine business remained robust Commenting, President and CEO of Iofina, Dr. Tom Becker, stated: "I am delighted to announce another consecutive year of record iodine production for Iofina, with full-year 2020 production of 609.9 metric tonnes ('MT') of crystalline iodine. This production figure is testament to the dedication and resilience of our workforce and the Company which, despite being affected by the COVID-19 pandemic and a challenging macro environment, has performed strongly."Most notably during the period our newest plant IO#8 was completed on time and on budget, and a successful corporate debt restructuring has seen our balance sheet greatly strengthened, with the level of debt more than halved when compared to the figure two years ago."As we move into 2021, we are seeing increased demand and iodine sales commitments, while a recovering oil market will likely bring more drilling and workover activity than we saw in 2020, allowing us to continue delivering on our strategy to expand our iodine production. The Directors are also continuing to evaluate opportunities for both improving existing plants and constructing new plants as part of the Group's commitment to growth and increased profitability."The Company has made significant progress in 2020, it is in a stronger position than it has ever been, and the Directors look to the coming year with confidence as we exit the pandemic."2020 production and H1 2021 forecastIn 2020 (the "Period"), the Group produced record levels of crystalline iodine (609.9 MT). H2 production of 325.5MT was the highest half-year production total in Company history. The Company continued to execute its expansion program with its newest plant, IO#8, which commenced production in April. The Group's other iodine plants performed well and with oil prices now significantly higher than mid-year 2020, Iofina and its partners expect more drilling and workover activity throughout 2021 versus 2020, which is likely to provide more brine water to produce iodine. Iofina continues to work in conjunction with its partners to maximize the supply of iodide rich brine water to each of our IOsorb(R) plants.Iofina Resources' production forecast for H1 2021 is 285-305 MT of crystalline iodine (H1 2020: 284.4 MT). Exploration efforts are ongoing, and the Directors are carefully evaluating potential future iodine production locations as well as the overall iodine market to determine the best timing for future expansion.Iodine marketDespite lower demand for iodine in H2 2020, indications in 2021 suggest that the iodine market is recovering. Iofina has already taken on significant iodine orders for 2021 which will reduce inventories. Iodine prices peaked in early 2020 and have since come off their highs but remained stable. Despite COVID, Iofina sees spot iodine prices at the beginning of 2021 to be similar to the beginning of 2020 at approximately $32.5-36/kg for large quantity buyers. Although difficult to predict, Iofina expects iodine prices to be stable in H1 2021, however this will likely be dependent on the rate of global economic recovery.Diversification of productsOver several years, the Company and its Directors recognized the importance of diversification of products in our core chemical competencies. This diversification was important in 2020 as many sectors contracted. Iofina Chemical's non-iodine halogen-based products performed very well in 2020, contributing significantly to the profitability of the Group. Iofina will continue to invest in the diversification of products as it offers additional stability, particularly in difficult economic times. In 2021 Iofina Chemical plans to invest in a new production line to improve its largest non-iodine process to improve efficiencies, safety, and purity. The Group will continue to explore new products and business relationships to ensure future growth.Debt refinancingA major accomplishment in 2020 for the Group was the refinancing and reduction of debt. In September of 2020, Group debt was refinanced through First Financial Bank, Ohio. Current Group debt is less than half of debt two years ago and carries a much lower rate of interest. This allows the Group to utilize more profits to reinvest in the Company's growth.COVID-19 impactDuring the Period the COVID-19 pandemic had a significant impact on individuals as well as the global economy. Although the Group was not immune from the effects of this pandemic, it was not as affected as many other industries and performed well under the circumstances as management realised it needed to be more proactive during this Period.At the start of the Period Iofina was on track for a breakout year with the iodine market expanding, iodine prices rising and oil production in the USA at record levels. After the economy contracted due to COVID-19, iodine demand slowed in some industries, particularly the automotive and X-ray contrast sectors, which resulted in iodine prices flattening. As a result, Iodine inventories rose in H2 2020 which is not historically atypical for Iofina's business. Further, oil companies reduced drilling and work-over programs because of lower oil prices and thus, in H2 2020, brine water available for processing at some of Iofina's plants was slightly reduced.Despite all of these challenges, Iofina reacted and performed well in the Period through weathering the pandemic, and is poised for a strong 2021. The Company also has utilized and continues to explore government programs implemented to assist entities through the pandemic. Iofina also strengthened its Board of Directors by adding Mary Fallin, the most recent Governor of Oklahoma, as a Non-Executive Director.IofinaEXIn H2 2020, the Director's determined that due to a number of factors including an uncertain regulatory environment, the reduction of cannabinoid prices and the need to focus in core areas, that the Group would no longer expend resources in its subsidiary IofinaEX with the exception of completing the hemp seed investment. The Company and its partners will continue seed sales efforts to maximize return on this investment without any significant expenses.Enquiries:Dr. Tom BeckerCEO & PresidentIofina plcTel: +1 859 356 8000Christopher Raggett/Giles Rolls/Matthew Radley (corporate finance)Tim Redfern (ECM)finnCap LtdTel: +44 (0)20 7220 0500Media Contact:Charles Goodwin/Joe BurgessYellow Jersey PR LimitedTel: +44 (0)7747 788 221About Iofina:Iofina plc (AIM: IOF) is a vertically integrated Company that specialises in the production of Iodine and the manufacturing of specialty chemical products. As the second largest producer of iodine in North America, it comprises three USA entities; Iofina Resources, Iofina Chemical and IofinaEX.LEI: 213800QDMFYVRJYYTQ84ISIN: GB00B2QL5C79Iofina ResourcesIofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET(R) IOsorb(R) technology. Iofina currently operates five producing IOsorb(R) plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.Iofina ChemicalIofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine based products for over 35 years.IofinaEXIofina's newest subsidiary, IofinaEX, is fully licensed to process hemp in the state of Kentucky and holds an investment in a hemp seed production project.www.iofina.comThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.END
12/1/2021
13:55
pinkpudycat: I doubt Iofina’s share price is going anywhere until the management issue is resolved. What is happening with OUR $1m the puppet agreed to lend his master?? The fact we had heard nothing is a good indicator. There are always theories as to why a companies share price isn’t increasing, but the simple answer is “poor management = poor shareprice”
02/1/2021
16:59
naphar: Dividend is an interesting one. If they were to give a 1p dividend in 2021, that alone could have a significant impact on share price. But it would cost them about £2m in cash. It would represent about a 7.5% yield at current share price and about 3.3% at 30p share price. I look forward to the day they have enough free cash flow they feel they can do that instead of investing in new plants or repaying debt. But at the moment I feel 1p would be too much. Here’s an idea though... assuming they get back the $900k seed money with at least $400k profit, so $1.3m, they could consider using that to pay a special one off dividend of 0.5p without adversely impacting today’s cash position. Whether loan covenants would allow that is a different topic. But not would make for a nice “apology”;
31/12/2020
13:35
zendo102: A bit of year end reflection: Back on the 3rd of September this year (post 800) I gave my view on the refinancing deal and the share price, and I suggested alternative assets that might have a better return than IOF by the end of 2020. I thought I'd return to that post to see how things have shaped up. So almost 4 months ago I wrote: ----------- "Agreed. I don't see any point buying now. Even if a great finance deal is signed, the price will shoot up for a day or two and then start drifting down again. It takes time for a serial disappointer to turn around. People have been burned, people are fully-invested, people are looking at that chart and don't want to be sucked in to hype, people are worried about the mismanagement of our funds on some random seeds scheme, people have seen that the iodine price is under a bit of pressure, people have decided to invest in the next hot thing instead? There are a whole host of reasons not to invest. And then there is the issue of plant builds. If IO9 comes along, how much will it actually add to the share price? Let's say it produces 150 tonnes of iodine a year and that it costs IOF $25 dollars per kg to produce after all expenses. So what's the profit? $10 x 150 tonnes x 1,000 kg x 0.85 (removing water content) = $1.275 m = £958,646 Shares in issue = 191.86 million so that makes a profit of £0.005 per share. Put that on a p/e of 10 (for an out-of-favour company) and we get an additional 5p on the share price. That's it. 5p. And that's not taking into account the risk of actually getting it built. Now 5p on the current share price would actually be quite a good percentage return, but is 5p "taking the lid off" the share price? So, which of the following will have the best return by the end of the year? 1. Iofina @ 13.6p (We are undervalued and we are going to take the lid off!) 2. A bet on Donald Trump to win the US elections @ evens (You can get evens on Biden as well, but incumbent presidents have a habit of being returned for a second term) 3. Royal Dutch Shell @ £10.40 (Can it really sink any lower?) 4. Bitcoin @ £8,150 (How do you value it anyway? Will it get back to £14,000?) 5. Aave - the LEND token @ 46.6p (DeFi is going to blow traditional finance out of the water.) I recently took one of these options. It wasn't Iofina. I continue to hold what I have, but I won't buy more. I can't imagine I'm the only one in this boat." ----------- So back to the present day - how have those picks done? 1. Iofina @ 13.6p => now 13p (Yahoo) or 12.33p (Google) and with a dodgy year-end drop): DOWN 4.4% - 9.3% 2. A bet on Donald Trump to win the US elections @ evens: DOWN 100% - probably!?! 3. Royal Dutch Shell @ £10.40 => now £12.59: UP 21.1% 4. Bitcoin @ £8,150 => now £21,013: UP 257.8% 5. Aave - the LEND token @ 46.6p => now 62.5p: UP 34.1% (The lend token is being converted to the AAVE token.) Bitcoin is by far and away the best performer, with a staggeringly MASSIVE 257% increase. However, any combination of 3, 4 and 5 would have done you well. IOF got a good refinancing deal, but as I suggested, the price has gone nowhere. Hopefully however, next year IOF will recover some of its glory as it shakes off a lot of the negative sentiment. My finger-in-the-air guess for the year end of 2021 is 26p-31p (but of course DYOR). Anyone else care to take a stab at the share price for 2021? By the way, despite my belief that there is a potential doubling here, I still won't be buying any more - my bag is big enough already. Good luck all IOF holders for 2021.
17/12/2020
10:46
madchick: They still have to buy the shares. It's only advantageous to the holders of the options if the share price goes up as only then will they get a profit. I believe they have been offered at a premium price in the past which is arguably misleading as shareholders get excited and thin it's a dead cert the share price will go up and often the options are never realisable ( in other companies as well). The board aren't milking salaries like in some other companies. I don't see this as problematic.
17/12/2020
10:19
zendo102: naphar Thanks for going back through previous RNSs to find all the details about outstanding options. However, my take is the opposite. 2018 - Here are some options @30p you can take if the price goes above 30p. That will REALLY incentivise management to get the share price up. 2020 - Oh, dear. The share price performance has been absolute cr@p. Let’s incentivise management by giving them options @12.5p. That will REALLY incentive management. What this tells me is IOF don’t think we will be going to 30p any time soon and they are lowering the bar on the options to “make sure” they get some money out of the company. The market reaction this morning says it all. In brokerspeak, IOF for me has just moved from OVERWEIGHT to UNDERWEIGHT.
17/12/2020
00:08
naphar: They are options, they are not restricted stock units, meaning they have not been given shares. The exercise price is yesterday’s closing price, I don’t think that’s unusual. They will only make a gain if the share price goes up and they can exercise them making a profit. They have not been given free shares they can sell tomorrow to cash in. I would be up in arms if they had. What has happened is relatively normal practice. Timing seems a bit odd, it was June 2018, July 2019 and now December 2020. 2018 and 2019 do not seem to have been at share price lows so there’s not a pattern of choosing the allotment time to suit. Maybe they changed the time of year they plan to allot options. Who knows. Ultimately whilst I would have preferred the strike price to have carried a premium, it didn’t on any of those issues from the 2018 option plan in either 2018 or 2019. So I would not have expected a premium and it’s probably not written into the guideline of the 2018 option plan. Interestingly the last of the 2008 option plan options that were issued in 2018 (I see no option announcements between 2014 and end 2017, are at 30p and will expire at start July 2021. So they have some incentive to get us significantly above that level by then if they can. Otherwise those options will lapse and potential gain from those is gone. If they can get us to 50p by end of June, with them taking a gain in the process, I will be very happy to get to 50p personally. I think their interests are aligned. Of course they have been given the right to make that gain and they haven’t paid for it as shareholders have, and they haven’t (Lance excluded and others to a much lesser extent) lost out on the ride down to these levels. Getting share price back up is what’s important now... it’s in their interests to do so.
16/12/2020
14:29
activmojo: Debt Refinanced, Production on Track Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update to the market regarding its activities during the third quarter ("Q3" or the "Period") of 2020. During the Period, the Company produced 170.8 metric tonnes ("MT") of crystalline iodine from its five operating IOsorb® plants in Oklahoma versus 167.3 MT in the same Period in 2019. The Company is on track to achieve the lower end of its 340-360 MT H2 forecast. The Company has produced 455MT of crystalline iodine in the nine months to 30 September 2020. IO#4 experienced a brief pause in activity during Q3 as our partner performed some required maintenance work at their disposal well. In conjunction with this work, Iofina executed planned improvements to the engineering of its water take-up system at the same site, with a view to increasing the amount of brine available. The Company has initiatives ongoing with its partners at all of its iodine production sites aimed at increasing water volumes available for processing at each IOsorb® plant. Iodine prices and demand have softened recently. Iodine prices began the quarter above $35/kg and Iofina now sees iodine prices for large quantities in the $33-35/kg on the spot market. These prices are still above the price range of around $32/kg for the same period last year, and the Company remains well placed to deliver good margins on its sales. The outlook for iodine prices and demand is likely to be directly related to the rate of the global economic recovery. The automotive sector, which utilises cuprous iodide and other iodides as heat stabilising agents, is already showing improvement and the health care applications of iodine products are increasing, but are not as yet at levels we experienced pre-COVID-19. In September 2020, the Group announced that it had refinanced its entire debt with First Financial Bank of Ohio. The debt refinance included a 7-year $10m term loan and a revolving line of credit of up to $8m. Initially the company has drawn $3m on the line of credit. Interest rates on Company debt have been lowered from 7.5% to below 4%. Significantly, since March 2019 the Group has reduced its debt from $25.6m to just below $13m, thus achieving substantial reductions in both debt and interest outgoings moving forward. Commenting, President and CEO Dr. Tom Becker, stated: "Iofina is currently in the strongest position it has ever been, both operationally and financially. We are on track for record iodine production in 2020, iodine prices are still strong, and our debt has been refinanced and significantly reduced. These factors in combination with consistent production diversified across plants and product lines, as part of a prudent growth strategy, have allowed Iofina to continue to excel in spite of the global economic issues caused by the COVID-19 pandemic."
09/11/2020
16:49
zendo102: So, Trump promises lower drug prices, threatening the drug companies’ profits. The first market day after Biden is confirmed as president elect, Pfizer announces a new vaccine and share prices soar. So, guess who they wanted as president? Anyway, with this vaccine news and the robustness of IOF and its low and unmoved share price, I would suggest that the risk to reward ratio on this share is not going to be better than right now. Is that the sound of the bell marking the bottom? Is that the sound of Mr Becker pulling out some crisp green notes from his pocket to take a punt? No investment advice intended of course.
Iofina share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IOF
Iofina
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 09:19:33